MILabs

MILabs is a developer and manufacturer of advanced preclinical imaging systems, offering a flexible portfolio of SPECT, PET, CT, and optical imaging modules. Acquired by Rigaku in 2021, the company leverages decades of scientific leadership to deliver high-resolution, multimodal platforms that enable researchers to visualize and quantify biological signals with exceptional clarity. Its core value proposition is providing scalable, integrated workflows that reduce experimental variability, support a wide range of study designs, and generate robust, reproducible evidence for academic and pharmaceutical research.

Modular, high-resolution preclinical imaging platform integrating SPECT, PET, CT, and optical imaging modalities within a unified software workflow for simultaneous or sequential multimodal data acquisition.

MILabs competes in the preclinical imaging market against large, diversified players like Bruker and PerkinElmer, as well as specialized firms. Its key differentiators are its ultra-high-resolution SPECT capabilities, true simultaneous multimodality (e.g., PET/SPECT) in the VECTor system, and a flexible, modular platform designed for workflow efficiency and reproducibility.